Last reviewed · How we verify
MB12066
At a glance
| Generic name | MB12066 |
|---|---|
| Also known as | beta-lapachone |
| Sponsor | Yungjin Pharm. Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers (PHASE1)
- Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis (PHASE2)
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers (PHASE1)
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB12066 CI brief — competitive landscape report
- MB12066 updates RSS · CI watch RSS
- Yungjin Pharm. Co., Ltd. portfolio CI